| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/18/2005 | EP1530471A1 Inhalation medicaments containing a novel anticholinesterase drug in conjunction with corticosteroids and betamimetic drugs |
| 05/18/2005 | EP1530470A1 Selective estrogen receptor modulators containing a phenylsulfonyl group |
| 05/18/2005 | EP1530469A2 Transdermal dosage form comprising an active agent and a salt and free-base form of an antagonist |
| 05/18/2005 | EP1530467A2 Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| 05/18/2005 | EP1530466A2 Use of lck inhibitor for treatment of immunologic diseases |
| 05/18/2005 | EP1530465A1 Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| 05/18/2005 | EP1530464A1 Aerosol formulation for inhalation containing an anticholinergic agent |
| 05/18/2005 | EP1530463A1 L-arginine containing pharmaceutical composition |
| 05/18/2005 | EP1530462A1 1-phenyl-2-dimethylaminomethyl cyclohexane compounds used for the therapy of depressive symptoms, pain, and incontinence |
| 05/18/2005 | EP1530461A1 Transdermal administration of (r)-3,3-diphenylpropylamine monoesters |
| 05/18/2005 | EP1530460A2 A process for manufacture of stable oral multiple units pharamceutical composition containing benzimidazoles |
| 05/18/2005 | EP1530459A2 Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment |
| 05/18/2005 | EP1530456A2 Non-vesicular cationic lipid formulations |
| 05/18/2005 | EP1530455A1 A pharmaceutical formulation and its use in the treatment of inner ear diseases |
| 05/18/2005 | EP1476194A4 Compositions and methods for preservation of food |
| 05/18/2005 | EP1467991B1 Prucalopride-n-oxide |
| 05/18/2005 | EP1430030B1 N-type calcium channel antagonists for the treatment of pain |
| 05/18/2005 | EP1404656B1 Benzimidazole derivatives for treating microglia-activation associated diseases such as inflammatory, allergic, infectious or autoimmune diseases |
| 05/18/2005 | EP1392290B1 Use of certain substituted pyrrolidones such as piracetam in the treatment of viral and other diseases |
| 05/18/2005 | EP1326502B1 Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate |
| 05/18/2005 | EP1317430B1 (2-azabicyclo [2.2.1]hept-7-yl)methanol derivatives as nicotinic acetylcholine receptor agonists |
| 05/18/2005 | EP1301502B1 Compounds and their use as glycine transport inhibitors |
| 05/18/2005 | EP1301184B1 Valproic acid and derivatives thereof as histone deacetylase inhibitors |
| 05/18/2005 | EP1265860B1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
| 05/18/2005 | EP1263724B1 Novel compounds |
| 05/18/2005 | EP1263421B1 The dual inhibitor of cholesteryl ester and wax ester synthesis avasimibe for treating sebaceous gland disorders |
| 05/18/2005 | EP1259484B1 Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion |
| 05/18/2005 | EP1233787B8 Product inhibiting transduction of g heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment |
| 05/18/2005 | EP1224204B1 Non-aromatic estrogenic steroids with a hydrocarbon substituent in position 11 |
| 05/18/2005 | EP1224195B1 C-aryl glucoside sglt2 inhibitors |
| 05/18/2005 | EP1186302B1 Ocular tension lowering composition for topical adminstration |
| 05/18/2005 | EP1176139B1 Medicinal compositions with 2.2.1] and 3.1.1] bicycloskeleton antagonistic to both of pgd 2?/txa 2? receptors |
| 05/18/2005 | EP1173185A4 Increased fertility and improved fetal development drug |
| 05/18/2005 | EP1161530B1 Protein for blocking platelet adhesion |
| 05/18/2005 | EP1098885B9 Imidazole compounds and their use as adenosine deaminase inhibitors |
| 05/18/2005 | EP1076652B1 N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| 05/18/2005 | EP1007058B1 Use of (n)-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections |
| 05/18/2005 | EP1007050B1 Olanzapine for treating substance abuse |
| 05/18/2005 | EP0946173B1 Preparation of 3-fluoro oxindole derivatives |
| 05/18/2005 | EP0884317B1 Active oxygen scavengers containing pterin derivatives |
| 05/18/2005 | EP0839055B1 Modified methioninase, its use, recombinant host cells producing high levels of methioninase and method for purifying methioninase |
| 05/18/2005 | EP0820461B1 Aryl-ester phosphoramidate derivatives of 2',3'-didehydronucleosides |
| 05/18/2005 | EP0755254B1 Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists |
| 05/18/2005 | EP0662137B1 Gene transcription and ionizing radiation: methods and compositions |
| 05/18/2005 | CN1617928A Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| 05/18/2005 | CN1617890A Cyclodextrin grafted biocompatible amphiphilic polymer and methods of preparation and use thereof |
| 05/18/2005 | CN1617884A Beta-amyloid binding factors and inhibitors thereof |
| 05/18/2005 | CN1617879A 17alpha-alkyl-17beta-oxy-estratrienes and intermediates for the production thereof, and use of said 17alpha-alkyl-17beta-oxy-estratrienes for producing medicaments and pharmaceutical preparations |
| 05/18/2005 | CN1617877A Use of phosphonate nucleotide analogue for treating hepatitis b virus infections |
| 05/18/2005 | CN1617875A Crystalline cefdinir potassium dihydrate |
| 05/18/2005 | CN1617874A Hexacyclic compounds |
| 05/18/2005 | CN1617871A Purine derivatives as purinergic receptor antagonists |
| 05/18/2005 | CN1617870A N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds |
| 05/18/2005 | CN1617869A 4-(piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as urotensin ii receptor antagonists |
| 05/18/2005 | CN1617868A Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| 05/18/2005 | CN1617865A Phenylalkynes |
| 05/18/2005 | CN1617864A Thiadiazoline derivative |
| 05/18/2005 | CN1617862A Novel 1, 2, 4-thiadiazole derivatives as melanocortin receptor modulators |
| 05/18/2005 | CN1617859A 5-sulfanyl-4h-1, 2, 4-triazole derivatives and their use as a medicament |
| 05/18/2005 | CN1617858A Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-1) |
| 05/18/2005 | CN1617857A 2'-halo-3', 5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivative and the use thereof as a drug for curing urinary incontinence |
| 05/18/2005 | CN1617856A Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them |
| 05/18/2005 | CN1617855A Inhibitors of cytosolic phospholipase A2 |
| 05/18/2005 | CN1617854A Pheny(alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity |
| 05/18/2005 | CN1617852A Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors |
| 05/18/2005 | CN1617849A Hiv整合酶抑制剂 Hiv integrase inhibitors |
| 05/18/2005 | CN1617755A Fpt inhibitor and use of other anti-tumor agent in combination in preparing anticancer drug |
| 05/18/2005 | CN1617746A Infection-resistant medical devices |
| 05/18/2005 | CN1617744A Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors |
| 05/18/2005 | CN1617743A New pharmaceutical combinations for nos inhibitors |
| 05/18/2005 | CN1617742A Methods for treating cancer by using tumor-derived dentrical cell inhibitory factor antagonist in combination with toll-like receptor agonist |
| 05/18/2005 | CN1617739A Methods and compositions for treating lesions of the respiratory epithelium |
| 05/18/2005 | CN1617738A Catheter composition and uses thereof |
| 05/18/2005 | CN1617736A Vaccine and method for treatment of motor neurone diseases |
| 05/18/2005 | CN1617733A Method of treatment of gastrointestinal disease and polymeric composition for use therein |
| 05/18/2005 | CN1617731A Use of DSRNAs in strategic therapeutic intervention of highly active antiretroviral therapy |
| 05/18/2005 | CN1617730A Compositions and methods for enhancing corticosteroid delivery |
| 05/18/2005 | CN1617729A Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia |
| 05/18/2005 | CN1617728A Antidiabetic formulation and method |
| 05/18/2005 | CN1617727A Selective dopamin D3 receptor agonists for the treatment of sexual dysfunction |
| 05/18/2005 | CN1617726A N4-acylcytosine nucleosides for treatment of viral infections |
| 05/18/2005 | CN1617725A Tyrosyl derivatives and their use as P2X7 receptor modulators |
| 05/18/2005 | CN1617724A Neurotransmitter balance chemotherapy |
| 05/18/2005 | CN1617723A Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess therewith |
| 05/18/2005 | CN1617722A Nicotin-or isonicotin benzothiazole derivatives |
| 05/18/2005 | CN1617721A Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and use thereof |
| 05/18/2005 | CN1617720A Use of pramipexole to treat amyotrophic lateral sclerosis |
| 05/18/2005 | CN1617719A Combination comprising a P-GP inhibitor and an anti-epileptic drug |
| 05/18/2005 | CN1617718A N-aryl-N'-arylcycloalkyl-urea derivatives as MCH antagonists for the treatment of obesity |
| 05/18/2005 | CN1617717A Pharmaceutical compositions of amlodipine and atorvastatin |
| 05/18/2005 | CN1617716A Heterocycle derivatives and methods of use |
| 05/18/2005 | CN1617715A Treating muscle wasting with selective androgen receptor modulators |
| 05/18/2005 | CN1617713A Ultrapure oral fludara formulation with a fast releasing active substance |
| 05/18/2005 | CN1617712A Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist |
| 05/18/2005 | CN1617711A Liposomal delivery of vitamin E based compounds |
| 05/18/2005 | CN1617710A Liposome composition for delivery of nucleic acid |
| 05/18/2005 | CN1617709A Stable topical formulation of clarithromycin |
| 05/18/2005 | CN1617704A Composition comprising at least one oxazolin for inhibiting langerhans cell migration, and uses thereof |
| 05/18/2005 | CN1617703A Composition comprising at least one alkanolamide for inhibiting langerhans cells migration, and uses thereof |
| 05/18/2005 | CN1617691A Prevention and treatment of androgen-deprivation induced osteoporosis |